)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
scPharmaceuticals
scPharmaceuticals (SCPH) investor relations material
scPharmaceuticals has been acquired by MannKind Corporation
scPharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Net FUROSCIX revenue reached $16 million in Q2 2025, up 99% year-over-year, with 20,200 doses filled and strong adoption in both cardiology and chronic kidney disease following the CKD launch in April 2025.
Cardiology drove most Q2 dose growth, while nephrology showed rapid prescriber uptake and is expected to contribute meaningfully in Q3 and beyond.
The number of unique prescribers rose to approximately 4,700, reflecting expansion in both cardiology and nephrology.
FUROSCIX received 3-year FDA exclusivity in October 2024, preventing approval of competing subcutaneous furosemide products until October 2025.
Development of an 80mg/1mL autoinjector is underway, with sNDA submission on track for Q3 2025, aiming to reduce COGS and boost market penetration.
Financial highlights
Q2 2025 product revenues were $16 million, up from $8.1 million in Q2 2024; cost of product revenues rose to $5 million from $2.3 million year-over-year.
Net loss for Q2 2025 was $18 million, compared to $17.1 million in Q2 2024; net loss per share was $0.34.
Cash and cash equivalents stood at $40.8 million as of June 30, 2025, down from $75.5 million at year-end 2024.
Gross to net discount for FUROSCIX was 27% in Q2, expected to approach 30% in Q3 due to Medicare Part D redesign.
Operating expenses for Q2 2025 were $30.3 million, up from $22.5 million in Q2 2024, driven by increased R&D and SG&A costs.
Outlook and guidance
Anticipates continued strong growth in nephrology and IDN segments, with nephrology expected to have a meaningful impact starting in Q3.
Medicare Part D redesign is now a tailwind, with more patients reaching out-of-pocket maximums, supporting prescription growth and fill rates.
A 3.5% price increase for FUROSCIX is effective July 1, 2025.
sNDA submission for the autoinjector is on track for Q3 2025, expected to reduce COGS by 75% and boost penetration.
Management expects continued operating losses as commercialization expands and R&D investment continues.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from scPharmaceuticals
- Strong growth, improved access, and pipeline expansion position FUROSCIX for continued success.SCPH
Maxim Group’s 2024 Healthcare Virtual Summit - Q3 revenue up 24% sequentially and 164% year-over-year, with major new financing secured.SCPHQ3 2024
- FUROSCIX prepares for CKD launch, targeting a $3B market with strong clinical and financial momentum.SCPHStatus Update
- Rising repeat prescriptions, new indications, and product innovation set the stage for rapid growth.SCPHH.C. Wainwright 26th Annual Global Investment Conference 2024
- Q2 revenue up 33% with FDA label expansion and $175M financing, but losses increased.SCPHQ2 2024
- Rapidly growing subcutaneous furosemide sees strong adoption, with major expansion ahead.SCPHJefferies 2024 Global Healthcare Conference
- Label expansion, Medicare changes, and new delivery tech position FUROSCIX for strong 2025 growth.SCPHLeerink’s Global Healthcare Conference 2025
- Medicare redesign and CKD launch position FUROSCIX for accelerated growth in 2024-2025.SCPHTD Cowen 45th Annual Healthcare Conference
- Furoscix expands home-based heart failure care, with CKD approval and auto-injector launch imminent.SCPHOppenheimer 35th Annual Healthcare Life Sciences Conference 2025
- Strong revenue growth and new CKD approval set the stage for accelerated expansion in 2025.SCPHQ4 2024
scPharmaceuticals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing products for subcutaneous drug delivery. The company specializes in creating innovative solutions that enable the administration of therapies outside of traditional healthcare settings, aiming to improve patient outcomes and reduce healthcare costs. scPharmaceuticals' products are designed for self-administration, offering convenience for patients with chronic conditions. Its approach integrates drug formulations with advanced delivery technologies to provide effective treatments across a range of therapeutic areas. The company is headquartered in Burlington, Massachusetts, and its shares are listed on the NASDAQ.